ArticleFrontiers in oncology2026
Survival outcomes of low-dose and high-dose bevacizumab front-line maintenance in advanced high-grade serous ovarian cancer: a propensity score-matched real-world study.
Tao Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.